DotLab, a San Francisco, CA-based personalized medicine company for women’s health, secured $10m in Series A funding.
The round was led by CooperSurgical, with participation from Tiger Global Management and Luxor Capital Group, as well as the law firm Wilson Sonsini Goodrich & Rosati.
The company plans to use its funds to further clinical validation, expand market access, and continue to grow our team in the pursuit of our goals.
Led by CEO Heather Bowerman, DotLab is a technology company which brings personalized medicine to women’s healthcare, starting with non-invasive, accurate test for endometriosis, which combines novel biomarkers with machine learning.
The company partnered with researchers at Yale University to evaluate the performance of the test relative to laparoscopy in patients with and without endometriosis across multiple clinical cohorts.